News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Helix Biopharma (CC:HBP) Signs L-DOS47 Manufacturing Agreement With QSV Biologics, Ltd.


12/20/2005 12:39:27 PM

Helix BioPharma Corp. (Helix; TSX, FSE: "HBP") today announced that it has signed an agreement with Edmonton, Alberta-based QSV Biologics (QSV) to develop the cGMP manufacturing process for L-DOS47.

Read at Canada NewsWire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES